EP1169061A1 - Therapie combinee pour le traitement du glaucome - Google Patents
Therapie combinee pour le traitement du glaucomeInfo
- Publication number
- EP1169061A1 EP1169061A1 EP99912458A EP99912458A EP1169061A1 EP 1169061 A1 EP1169061 A1 EP 1169061A1 EP 99912458 A EP99912458 A EP 99912458A EP 99912458 A EP99912458 A EP 99912458A EP 1169061 A1 EP1169061 A1 EP 1169061A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- iop
- lowering agent
- alkyl
- glutamate
- glutamate antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention relates generally to the field of ophthalmology.
- the invention relates to the treatment of glaucoma using a combination of a glutamate antagonist to preserve visual field and an intraocular pressure lowering compound.
- IOP intraocular pressure
- glaucoma has historically been treated by medically and /or surgically lowering elevated IOP, for example, by the administration of IOP-lowering agents such as miotics, ⁇ and ⁇ / ⁇ adrenergic agonists, beta-blockers, and carbonic anhydrase inhibitors.
- IOP-lowering agents such as miotics, ⁇ and ⁇ / ⁇ adrenergic agonists, beta-blockers, and carbonic anhydrase inhibitors.
- factors other than IOP may play a role in the occurrence of visual field loss.
- Degeneration of retinal ganglion cells may be related to ischemia or mechanical distortion of the nerve fibers as they exit through the optic nerve head or from pathological perturbations of the retina.
- Retinal dysfunction may be related to ischemia or excitotoxicity.
- Excitotoxicity is neuronal injury due to excessive excitatory amino acid
- EAA EAA stimulation.
- glutamate is the major EAA that permits the bipolar and amacrine cells to communicate with the ganglion cell.
- excitotoxicity results from hypoxia, ischemia, hypoglycemia or trauma. (See, for example, Beal, M.F., “Mechanisms of excitotoxicity in neurologic diseases,” FASEB J.. 6:3338-3344 (1992); and Choi, D.W., "Excitotoxic cell death,” J. Neurobiol.. 23: 1261-1276 (1992).)
- Toxicity to the inner retina has been observed following intravitreal injection of EAAs following application of EAAs to the isolated animal retina or from exogenously applied glutamate to retinal ganglion cells in culture. See generally, Sattayasai, et al., "Morphology of quisqualate-induced neurotoxicity in the chicken retina," Invest. Ophthalmol. Vis. Sci.. 28:106-117 (1987); Tung et al., "A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick, Visual Neurosci..
- EAA receptors have been characterized as metabotropic or ionotropic. Activation of a metabotropic receptor affects cellular processes via G-proteins; whereas ionotropic receptors affect the translocation of mono- and divalent cations across the cell membrane. There are at least three ionotropic receptors that have been named for the agonist that preferentially stimulates the receptor. These receptors have been classified as: N-methyl-D-aspartate (NMDA); kainate; and AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid). These EAA receptors are differentially distributed to specific cells in the retina.
- NMDA N-methyl-D-aspartate
- AMPA 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid
- antagonists of the NMDA receptor are neuroprotective; however, not all antagonists of the diversely distributed EAA receptors are neuroprotective to the inner retina through antagonism of the NMDA receptor, Zeevalk et al., "Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity," Brain Res., 522:135-139 (1990)), and many of these EAA antagonists have significant CNS side-effects and are therefore not suitable for treating these degenerative diseases of the eye.
- the present invention is directed to the use of a glutamate antagonist and an IOP controlling agent, dosed separately or in combination for the treatment of persons suffering from glaucoma or ocular hypertension.
- the present invention involves the use of two types of agents to treat glaucoma and ocular hypertension.
- One agent is an IOP-lowering agent directed at preventing the damage to retinal ganglion cells brought on by mechanical, circulatory, and other poorly understood factors related to elevated IOP.
- the second agent is a glutamate antagonist used to prevent further damage to ganglion cells and optic nerve fibers from excitotoxicity.
- glutamate antagonist means an antagonist of the NMDA receptor channel complex.
- NMDA receptor antagonists include channel blockers (agents that operate uncompetitively to block the NMDA receptor channel); receptor antagonists (agents that compete with NMDA or glutamate at the NMDA binding site); and agents acting at the glycine coagonist site or any of several modulation sites (e.g., zinc, magnesium, redox, or polyamine sites).
- R 5 H, halogen, trifluoromethyl, Cl-4 alkyl, OH, Cl-4 alkoxy, benzyloxy, Cl-16 alkanoyloxy, benzoyloxy.
- WAY- 126251 (see Drug News Perspect 11(9), November 1998), memantine, and other compounds disclosed in WO 94/13275 to the extent they are suitable for chronic administration.
- At least one of the compounds of this invention are administered orally with daily dosage of these compounds ranging between 0.01 and 500 milligrams.
- the preferred total daily dose ranges between 1 and 100 milligrams.
- Non-oral administration such as, intravitreal, topical ocular, transdermal patch, parenteral, intraocular injection, or subconjunctival routes may require an adjustment of the total daily dose necessary to provide a therapeutically effect amount of the compound.
- the compounds can be inco ⁇ orated into various types of ophthalmic formulations for topical delivery to the eye. They may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions.
- Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound.
- the ophthalmic solutions may contain a thickener, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl- pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
- a thickener such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl- pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
- the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
- Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be inco ⁇ orated.
- the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8.
- the compounds will normally be contained in these formulations in an amount .001% to 5% by weight, but preferably in an amount of .01% to 2% by weight.
- 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the routine discretion of a skilled clinician.
- the preferred compound, eliprodil is orally bioavailable, demonstrates a low incidence of adverse effects upon administration, and effectively crosses the blood-brain barrier (Drugs of the Future, 1994, 19, 905-909) indicating that effective concentrations are expected in the target tissue, the retina.
- the compound is described in U.S. Patent No. 4,690,931 , the contents of which are inco ⁇ orated herein by reference.
- the IOP-lowering agents useful in the present invention include all presently known IOP-lowering pharmaceuticals, including, but not limited to, miotics (e.g., piloca ⁇ ine, carbachol, and acetylcholinesterase inhibitors); ⁇ and ⁇ / ⁇ adrenergic agonists (e.g., epinephrine, dipivalylepinephrine, para-amino clonidine and brimonidine); beta-blockers (e.g., betaxolol, S-betaxolol, levobunolol, carteolol, and timolol); prostaglandins and their analogues and derivatives, such as, compounds disclosed in U.S.
- miotics e.g., piloca ⁇ ine, carbachol, and acetylcholinesterase inhibitors
- ⁇ and ⁇ / ⁇ adrenergic agonists e.g., epinephrine
- carbonic anhydrase inhibitors e.g., acetazolamide, methazolamide, and ethoxzolamide, and compounds disclosed in U.S. Patent Nos. 5,153,192; 5,240,923; 5,378,703; and 4,797,41
- the preferred IOP-lowering agents are: timolol, betaxolol, S-betaxolol levobunolol, carteolol, piloca ⁇ ine, carbachol, epinephrine, dipivalyl epinephrine- ⁇ methyl dipivalylepinephrine, brinzolamide, dorzolamide, unoprostone, latanoprost, travoprost, apraclonidine, and brimonidine.
- IOP-lowering agents will be administered systemically, or if in a topical formulation, at a concentration of between 0.001 and 5.0 wt%, preferably, 0.01 to 2.5 wt%, but preferably 0.001 - 0.005 for prostaglandins.
- the IOP-lowering compositions of the present invention may additionally include components to provide sustained release and/or comfort.
- Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Patent Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are inco ⁇ orated herein by reference.
- the IOP-lowering compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents.
- antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Polyquad ® and other agents equally well-known to those skilled in the art.
- Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt%.
- agents which may be used to adjust the tonicity or osmolality of the formulations include: sodium chloride, potassium chloride, mannitol, dextrose, glycerin, and propylene glycol. Such agents, if utilized, will typically be employed in an amount between about 0.1 and about 10.0 wt%.
- compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts.
- the compositions are preferably aqueous suspensions or solutions.
- compositions of the present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions and solid compositions or devices.
- the first class, substantially non-aqueous liquids comprise an IOP-lowering agent and a second agent ("drug combination") dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
- vegetable and mineral oils such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil
- triglycerides such as the capric/caprylic triglycerides commonly used in foods and cosmetics
- liquid lanolin and lanolin derivatives such as the capric/caprylic triglycerides commonly used in foods and cosmetics
- perfluorohydrocarbons such as the capric/caprylic triglycerides commonly used in foods and cosmetics.
- the second class, semi-solid compositions comprise an IOP-lowering agent dissolved or suspended in one or more of the following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base, such as Plastibase®; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
- various types of petrolatum such as white, yellow, red and so on
- lanolin and lanolin derivatives such as gelled mineral oil having a hydrocarbon base, such as Plastibase®
- petrolatum and ethylene carbonate mixtures such as polyoxyl 40 stearate and polyethylene glycol.
- the third class, solid compositions or devices include non-erodible devices which are inserted into the conjunctival sac of the eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on).
- non-erodible devices which are inserted into the conjunctival sac of the eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on).
- bioerodible inserts described and detailed in US 4,540,408 (Lloyd) and US 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol.
- US 4,540,408 Lioyd
- US 4,730,013 Bodi et al.
- the present invention is also directed to methods of treating persons with glaucoma or ocular hypertension.
- At least one glutamate antagonist will be administered systemically and at least one IOP-lowering composition described above is applied topically to the affected eye(s) of the patient.
- the frequency and amount of dosage will be determined by the clinician based on various clinical factors.
- the methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/005423 WO2000054810A1 (fr) | 1999-03-12 | 1999-03-12 | Therapie combinee pour le traitement du glaucome |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1169061A1 true EP1169061A1 (fr) | 2002-01-09 |
Family
ID=22272341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99912458A Withdrawn EP1169061A1 (fr) | 1999-03-12 | 1999-03-12 | Therapie combinee pour le traitement du glaucome |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1169061A1 (fr) |
AU (1) | AU3082999A (fr) |
CA (1) | CA2368242A1 (fr) |
HK (1) | HK1040184A1 (fr) |
WO (1) | WO2000054810A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU766163B2 (en) | 1999-03-05 | 2003-10-09 | Duke University | C16 unsaturated fp-selective prostaglandins analogs |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US7186745B2 (en) | 2001-03-06 | 2007-03-06 | Astrazeneca Ab | Indolone derivatives having vascular damaging activity |
TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20080033053A1 (en) * | 2004-07-22 | 2008-02-07 | Wolfgang Curt D | Cross-Reference To Related Applications |
WO2006015075A1 (fr) * | 2004-07-26 | 2006-02-09 | Allergan, Inc. | Techniques de traitement d'etats pathologiques ophtalmiques |
EP1799264A2 (fr) * | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methodes et compositions de traitement de la douleur de migraine |
US20070167527A1 (en) * | 2006-01-13 | 2007-07-19 | Burke James A | Memantine for the normalization of visual acuity deficits |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
US20120322882A1 (en) | 2009-11-09 | 2012-12-20 | Allergan, Inc. | Compositions And Methods For Stimulating Hair Growth |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US9078854B2 (en) | 2010-07-29 | 2015-07-14 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
JP2021531327A (ja) * | 2018-06-19 | 2021-11-18 | セラ セラピューティクス エルエルシー | 眼圧降下剤、cnp化合物、nrp−b化合物、tie−2アゴニスト、または神経栄養剤を含む、緑内障または高眼圧症を治療するための徐放性薬剤送達系 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018812A1 (fr) * | 1995-11-17 | 1997-05-29 | Alcon Laboratories, Inc. | Therapie combinee pour le traitement du glaucome |
-
1999
- 1999-03-12 WO PCT/US1999/005423 patent/WO2000054810A1/fr active Application Filing
- 1999-03-12 CA CA002368242A patent/CA2368242A1/fr not_active Abandoned
- 1999-03-12 EP EP99912458A patent/EP1169061A1/fr not_active Withdrawn
- 1999-03-12 AU AU30829/99A patent/AU3082999A/en not_active Abandoned
-
2002
- 2002-02-19 HK HK02101195.9A patent/HK1040184A1/zh unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0054810A1 * |
Also Published As
Publication number | Publication date |
---|---|
HK1040184A1 (zh) | 2002-05-31 |
AU3082999A (en) | 2000-10-04 |
CA2368242A1 (fr) | 2000-09-21 |
WO2000054810A1 (fr) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6441047B2 (en) | Combination therapy for treating glaucoma | |
EP1169061A1 (fr) | Therapie combinee pour le traitement du glaucome | |
US6664286B1 (en) | Serotonergic 5ht2 agonists for treating glaucoma | |
US6271224B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
CA2502437C (fr) | Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome | |
EP1541151A1 (fr) | Traitement contre le glaucome a base d'inhibiteurs de rho kinase et de prostaglandines | |
JP2007217437A (ja) | カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法 | |
AU704938B2 (en) | Combination therapy for treating glaucoma | |
US6486208B1 (en) | Sustained release, and comfortable opthalmic composition and method for ocular therapy | |
US6264935B1 (en) | Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum | |
US5438060A (en) | Method of reducing elevated intraocular pressure | |
US6545045B1 (en) | Prostaglandin E agonists for treatment of glaucoma | |
EP1267847B1 (fr) | Agonistes de 5ht 2 permettant de controler la pression intra-oculaire elevee et de traiter le glaucome | |
US6200990B1 (en) | Neuroprotective agents having antioxidant and NMDA antagonist activity | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
EP1647274A1 (fr) | Remede contre le prurit comprenant un derive de piperidine comme principe actif | |
JP4300347B2 (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
EP3730137B1 (fr) | Agent thérapeutique du glaucome comprenant un agoniste fp et timolol | |
AU2004214563A1 (en) | Combination therapy for treating glaucoma | |
US5308849A (en) | Method of reducing elevated intraocular pressure | |
AU2001217709B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
EP0728480A1 (fr) | Utilisation d'ifenprodil pour le traitement de la pression intraoculaire élevée | |
EP1200079B1 (fr) | Derives de 2-aminotetraline destines au traitement du glaucome | |
US6927233B1 (en) | 5ht2 agonists for controlling IOP and treating glaucoma | |
EP0277814B1 (fr) | Utilisation de trifluorométhanesulfonamide contre le glaucome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011106 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20031031 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071124 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1040184 Country of ref document: HK |